Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
60 hedge funds and large institutions have $87M invested in Marinus Pharmaceuticals, Inc in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 21 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
17% more call options, than puts
Call options by funds: $3.6M | Put options by funds: $3.07M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 65 → 60 (-5)
19% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 21
59% less capital invested
Capital invested by funds: $210M → $87M (-$123M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
+$7.54M |
| 2 |
TBC
Three Bays Capital
Boston,
Massachusetts
|
+$5.62M |
| 3 |
6CM
683 Capital Management
New York
|
+$3.87M |
| 4 |
HT
HAP Trading
New York
|
+$2.26M |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$2.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ascend Capital
Orinda,
California
|
-$8.26M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.17M |
| 3 |
NC
Nexthera Capital
New York
|
-$7.55M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.98M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Squarepoint
New York
| – | -$158K | -4,845 | Closed |
|
|
DTL
77
Dynamic Technology Lab
Singapore
| – | -$146K | -4,491 | Closed |
|
78
TD Asset Management
Toronto,
Ontario, Canada
| – | -$137K | -4,200 | Closed |
|
|
JGC
79
J. Goldman & Co
New York
| – | -$53K | -1,632 | Closed |
|
|
DCM
80
Delpha Capital Management
New York
| – | -$24K | -731 | Closed |
|
MRNS Hedge Fund Activity: Q1 2018 in Review
60 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2018, worth a combined $87M — down 59% from $210M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of MRNS and 17 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 19 added.
The largest buyer was GMT Capital, opening a new position worth an estimated $7.54M. The largest seller was Ascend Capital, exiting entirely with an estimated $8.26M sold.
- 60 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2018, down from 65 in Q4 2017.
- Funds reported $87M of Marinus Pharmaceuticals, Inc stock for Q1 2018, down 59% quarter-over-quarter.
- 17 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2018 and 21 closed out, a net change of -4 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q1 2018 was GMT Capital, an estimated $7.54M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q1 2018 was Ascend Capital, an estimated $8.26M sold.
Based on aggregated 13F filings for Q1 2018.